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Preface 
 
 
This dissertation is a compilation of both published and unpublished work 
towards the goal of understanding the roles of Heat Shock Protein 70 (Hsp70) in 
cancer. Chapter 1 is primarily based on a review that has been submitted to Current 
Topics in Medicinal Chemistry, entitled “Allosteric Inhibitors of Hsp70: Drugging the 
Second Chaperone of Tumorigenesis.” This manuscript summarizes the pro-survival 
roles played by molecular chaperones as well as the efforts to pharmaceutically target 
Hsp70. Chapter 2 is derived, in part, from a manuscript where we adapted the 
rhoadcyanine, MKT-077, as a selective Hsp70 inhibitor. Using structure-guided design, 
we developed more potent and metabolically stable derivatives for use as chemical 
probes and clinical candidates. This citation is “Analogues of the Allosteric Heat Shock 
Protein 70 (Hsp70) Inhibitor, MKT-077, As Anti-Cancer Agents” 2013 ACS Med. Chem. 
Lett. 4(11): 1042-7. In Chapter 3, we use the most potent of the charged analogs, JG-
98, to explore the roles of Hsp70 in cancer. The major discovery of this work was that 
Hsp70 acts at a hub of multiple cell death pathways, capable of directing both apoptotic 
and necroptotic cell deaths. This work is being prepared for submission to Science. In 
Chapter 4, we made significant progress towards identifying the oncogenic roles played 
by individual members of the Hsp70 family. To achieve this goal, we developed JG-13, 
a neutral derivative of MKT-077 that selectively affects cytosolic Hsp70s. By comparing 
the effects of JG-13 with JG-98, we were able to parse out the differences between 
vii""
unique Hsp70 isoforms, and how they contribute to maintaining the cancer phenotype. 
A manuscript describing this work is in preparation. In Chapter 5, we discuss the 
implications of this work and present possible future directions. 
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Abstract 
 
 
 
 
Co-Chair: Jason E. Gestwicki; Co-Chair: Duxin Sun 
 
 The proper balance between protein synthesis, folding, and turnover is termed 
protein homeostasis, or proteostasis. Cancer cells are especially reliant on the activities 
of molecular chaperones, such as heat shock proteins 70 (Hsp70) and 90 (Hsp90), 
which are critical to protein quality control.  Hsp70 and Hsp90 collaborate to buffer 
cancer cells against unstable oncogenic mutations, and these chaperones are thought 
to prevent apoptosis during rapid metabolism and cell division. While Hsp90’s specific 
roles in cancer are relatively well described and inhibitors are being studied in multiple 
clinical trials, less is known about Hsp70.  
 In this thesis, we aimed to characterize Hsp70’s roles in cancer signaling. 
Towards this goal, we developed the first selective and potent inhibitors of Hsp70, 
based on the rhodocyanine MKT-077. We found that these molecules, including JG-98 
and JG-13, have potent cytotoxic activity in multiple cancer cell lines, with minimal effect 
on normal fibroblasts. Moreover, these compounds were highly synergistic with 
inhibitors of either Hsp90 or the proteasome. Using JG-98 as a chemical probe, we 
found that Hsp70 suppresses apoptotic cell death through a novel process dependent 
on RIP1 kinase. Further, under conditions in which apoptosis was inhibited, JG-98 
triggered a strong necroptotic phenotype, suggesting that Hsp70 helps regulate a key 
xvi""
cellular “decision” to proceed with either apoptosis or necrosis. Thus, Hsp70 shares 
some cellular roles in common with Hsp90, but also has important differences that might 
be exploited in the pursuit of anti-cancer agents with new mechanisms-of-action. 
 Hsp70 is actually a family with thirteen members in humans, and it is still unclear 
if these isoforms play distinct or overlapping roles in cancer. To better understand this 
question, we have made significant efforts towards designing small molecules that 
target cytosolic and mitochondrial Hsp70s specifically. These probes have the potential 
to further transform or understanding of Hsp70 as a cancer chaperone.  
 Taken together, these studies reveal that Hsp70 operates in a much more global 
cytoprotective fashion in cancer cells than previously suggested. This work also makes 
significant strides towards the development of improved chemotherapeutics targeting 
the protein quality control machinery. 
 "
1 
Chapter 1 
 
Protein Quality Control in Cancer: Drugging the Molecular Chaperones
1.1 Abstract 
 Cancer cells survive in the presence of a number of cytotoxic stresses that would 
normally result in cell death. To accomplish this feat, most cancers express elevated 
levels of molecular chaperones, especially heat shock protein 70 (Hsp70) and heat 
shock protein 90 (Hsp90). These chaperones stabilize numerous anti-apoptotic “clients”, 
including Raf-1, Akt-1 and Her2, providing resistance to cell death and protecting 
against radiation and chemotherapy. These pro-survival activities make Hsp70 and 
Hsp90 promising nodes for potential anti-cancer therapies. While inhibitors of Hsp90 are 
well known, progress in the development of Hsp70 inhibitors has proven more difficult. 
Hsp70 binds tightly to ATP through a highly conserved domain of the 
actin/hexokinase/Hsp70 superfamily, making it challenging to identify inhibitors that 
selectively compete with ATP for binding to the active site. Alternatively, some progress 
has been made on compounds that target important allosteric sites on the chaperone. In 
some cases, these allosteric pockets have been shown to control key protein-protein 
interactions between Hsp70 and its co-chaperones, providing multiple possible avenues 
for disrupting chaperone functions. In this chapter, we review the evidence linking 
Hsp70 to cancer signaling pathways and provide an update on recent progress in 
developing allosteric inhibitors. 
2 
1.2 Chaperones as Permissive Oncogenes 
Tumor cells typically express high levels of the molecular chaperones Hsp70 and 
Hsp90 (1-6). These chaperones are thought to be permissive of the cancer phenotype, 
in part, because they protect oncogenes from degradation. For example, many 
oncogenes contain destabilizing mutations or aberrant chromosomal translocations that 
would normally render the proteins prone to rapid turnover. However, unique to cancer 
cells, chaperones are found preferentially in complex with co-chaperones (7), which 
increases their activity and buffers against aberrant mutations. At the same time, 
chaperones also protect against the cytotoxicity that would normally occur in the 
presence of oxidative damage associated with rapid cell division (8, 9). Indeed, 
tumorigenesis is so dependent on the activity of chaperones, that cancer cells have 
been described as being “addicted” to these factors (10-12). Thus, Hsp90 and Hsp70, 
sitting at the intersection of multiple cell survival pathways, have emerged as potential 
hubs for anti-cancer drug development.   
 
1.3 Hsp90, “The Cancer Chaperone” 
 Hsp90 is an ATPase composed of an N-terminal domain that binds ATP, a 
middle domain that mediates homodimerization and a C-terminal domain (reviewed in 
(13)). All of these domains have been proposed to interact with clients. Hsp90 is active 
as a homodimer and recent structural insights have provided snapshots of Hsp90 in its 
various apo-, ATP- and ADP-bound states (14, 15). These structures have shown that 
nucleotide cycling in the N-terminal domains drive major conformational changes, 
including rotation of the two Hsp90 monomers from an open “V-state” to form a more 
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closed structure. These actions are thought to regulate the capture and release of 
Hsp90’s clients. Clients are typically stabilized by their interaction with Hsp90, while 
release from the chaperone is often associated with degradation.  
 There are three major categories of Hsp90 inhibitors, which are divided into 
categories based on their binding sites on the chaperone. The N-terminal domain is the 
site of binding for geldanamycin, its analogs and many other synthetic inhibitors, such 
as PU-H71, STA-9090 and NVP-AUY922. These molecules compete with ATP (16-19), 
and binding of these compounds appears to stall nucleotide cycling, trap an “open” state 
of the dimer and favor client release. In turn, release of clients from Hsp90 seems to 
restore their normal vulnerability to rapid degradation. More recently, compounds 
related to novobiocin, such as KU-174, have been found to interact near the C-terminus 
of Hsp90 (20, 21). Interestingly, these compounds also destabilize Hsp90 clients, 
despite the fact that they bind a distinct domain and don’t directly compete for binding to 
nucleotide. The mechanism of client degradation after binding novobiocin analogs is not 
yet clear, but it likely involves changes in allosteric communication or conformational 
shifts within Hsp90 that leads to reduced client interactions. Finally, some reported 
Hsp90 inhibitors impede interactions with co-chaperones (22-24). A variety of co-
chaperones, including p23, Aha1, Hop and cdc37 associate with Hsp90, regulating its 
ATPase activity and helping to guide its selection of clients (25, 26). As previously 
mentioned, complexes between Hsp90 and its co-chaperones are enriched in cancer 
cells (7), signifying that the oncogenic roles of Hsp90 are linked to cooperation between 
these factors. Consistent with this idea, compounds that inhibit protein-protein 
interactions between Hsp90 and its co-chaperones disrupt Hsp90 functions. Similar to 
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the other categories of inhibitors, these compounds also destabilize Hsp90 clients. For 
example, analogs of sansalvamide A bind the middle domain of Hsp90 and interrupt 
binding of Hsp90 to IP6K2 (27), while analogs of gedunin appear to selectively 
inactivate the co-chaperone p23 (22). It is interesting that many different compounds, 
operating at multiple binding sites on Hsp90, all disrupt client stability. These results 
suggest that Hsp90 is a sensitive, dynamic “machine” and that interrupting any of its 
various activities (e.g. ATP cycling, co-chaperone interactions) reduces its ability to 
protect clients. As will be discussed below, similar patterns are emerging for the Hsp70 
system, which seems to present parallel opportunities for inhibition. 
 Hsp90 binds to at least 1,000 proteins in the cell, including many pro-survival 
kinases and transcription factors (28-31). Many of the clients of Hsp90 have metastable 
domains, such as steroid-binding clefts, nucleotide-binding cassettes and latent protein-
protein interaction motifs. Binding of Hsp90 to these client proteins is thought to protect 
them from degradation by “hiding” the metastable regions from the protein quality 
control systems (32, 33). Accordingly, a diagnostic feature of Hsp90 inhibitors is that 
they destabilize multiple clients, including Akt, Raf-1, Her2, and Bcr-Abl (28-31). 
Interestingly, Hsp90 inhibitors typically have little effect on normal cells, such as 
fibroblasts. It isn’t yet clear why some chaperone clients become so sensitive in cancer 
cells, but it seems plausible that the clients in non-cancerous cells may fold more 
effectively and be less dependent on Hsp90 function. Based on this logic, Hsp90 has 
been called the “cancer chaperone” (12, 34, 35).  
 Several Hsp90 inhibitors, mostly targeting the N-terminal domain, have entered 
clinical trials as anti-cancer therapies (35-38). While Hsp90 inhibitors exhibit potent 
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activity against a variety of cancer lines, including those already resistant to 
conventional chemotherapeutics (39, 40), the results of clinical trials so far suggest that 
the efficacy of these compounds may be short lived. Specifically, tolerance to Hsp90 
inhibitors occurs relatively rapidly, with eventual clinical relapse (41-44). Though the 
exact mechanism for this acquired resistance is unclear, one potential explanation is 
that Hsp70 may compensate for loss of Hsp90 function. Indeed, one biomarker for N-
terminal Hsp90 inhibitors is that they activate a stress response, dramatically elevating 
the levels of Hsp70 and other chaperones (44-47). In turn, high levels of Hsp70 may be 
able to partially compensate for loss of Hsp90 function in cancer cells, suggesting that 
Hsp70 may be an additional facilitator of oncogenic activity.  
 
1.4 Hsp70: the Second Chaperone of Tumorigenesis 
 Hsp70 consists of a 44kDa nucleotide-binding domain (NBD) and a 26kDa 
substrate-binding domain (SBD) (Figure 1.1) (48). The NBD includes a nucleotide-
binding cassette of the Hsp70/actin/hexokinase superfamily that binds very tightly to 
ATP (Kd ~ 0.1 to 0.5 µM) (49) and has intrinsic hydrolysis activity (50). The SBD is 
comprised of a β-sandwich subdomain and a α-helical “lid”. Hydrophobic regions in 
client proteins bind in a groove of the β-sandwich that is “covered” by the lid (51). The 
NBD and SBD are connected by a short, hydrophobic linker that is important for inter-
domain allostery (52, 53). 
 Detailed NMR and crystallography studies have shown that Hsp70 is a highly 
flexible protein that is regulated by multiple allosteric mechanisms (54). For example, 
the two lobes of the NBD collapse onto each other in response to hydrolysis of ATP 
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(55). This “scissor” motion helps communicate nucleotide status in the remainder of the 
protein, because the NBD is closely associated with the SBD in the ATP-bound state, 
while hydrolysis releases this inter-domain contact (56-58). A consequence of this 
motion is that the helical lid moves from an “open” configuration impinging on the NBD, 
to a “closed” state on the SBD (Figure 1.1). These coordinated motions occur over 
dozens of Ångstroms and involve rearrangements of nearly every subdomain. 
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 Allosteric motions in Hsp70 are further regulated by binding to co-chaperones. 
Hsp40s (or J-proteins) are co-chaperones that bind to Hsp70 via a conserved J domain. 
Binding of the J domain in a region between the NBD and SBD helps release their 
interdomain contacts, mobilizing the linker region, and promoting ATP hydrolysis (56). 
After hydrolysis, ADP is replaced with ATP by another co-chaperone class, nucleotide-
exchanged factors (NEFs). NEFs, such as BAG1, make contacts with the two lobes of 
Hsp70’s NBD and favor the “open” configuration (59). This allosteric motion allows ADP 
to be released and ATP to bind. Finally, tetratricopeptide repeat (TPR) domain proteins, 
such as Hsc70-organizing protein (HOP) and the C-terminal Hsc70-Interacting protein 
(CHIP), interact at the C-terminal EEVD motif of the SBD (60). The TPR co-chaperones 
appear to coordinate “hand-off” of clients to other pathways. For example, HOP binds to 
both Hsp70 and Hsp90 and it has been shown to facilitate transfer of clients between 
the chaperones, while CHIP is an E3 ligase that ubiquitinates substrates, thus targeting 
them for proteasomal degradation. Thus, these various families of co-chaperones 
(Hsp40s, NEFs and TPR proteins) bind Hsp70 and help regulate its cellular actions. 
Moreover, there are ~40 Hsp40 genes in human cells, in addition to dozens of NEFs 
and TPR-domain co-chaperones. It is thought that specific combinations of Hsp70s and 
individual members of the Hsp40 family may be partially dedicated to subsets of 
chaperone activities (61-63), a model supported by recent genetic studies (64, 65). 
Thus, the combinatorial assembly of co-chaperones onto Hsp70 is thought to generate 
a series of distinct complexes that may execute the specific actions of the chaperone.  
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 Hsp70 is thought to have a large number of clients. Indeed, studies using peptide 
arrays have suggested that the clients of Hsp70 include virtually any protein with 
exposed hydrophobic regions (66). NMR and crystallography studies have supported 
this idea by showing that Hsp70 makes most of its contacts with the amide backbone of 
client peptides (48, 67). This mode of binding would be predicted to allow binding to 
most, if not all, proteins (68). Thus, the theoretical clients of Hsp70 would appear to 
include the same pool governed by Hsp90, in addition to a wide range of other proteins. 
Indeed, several studies have shown that knockdown of Hsp70 leads to degradation of 
oncogenic Hsp90 clients, such as Akt and Her2 (69-74). However, one might initially 
presume that destabilization of all presumed Hsp70 clients might be broadly cytotoxic to 
all cells, not just cancer cells. However, experimental studies have shown that this is not 
the case, as will be discussed below. Accordingly, one of the major outstanding 
questions in the field is how Hsp70 clients are chosen, how these clients might be 
different in cancer cells, and how Hsp70 and its co-chaperones might cooperate in this 
process. 
 There are approximately 13 different Hsp70 genes in humans and members of 
the Hsp70 family are found in the cytosol, the nucleus and all of the organelles (75). The 
major cytosolic family members are Hsc70 (HSPA8), which is constitutively expressed, 
and Hsp72 (HSPA1), which is expressed in response to stress. Cancer cells appear to 
have elevated Hsp72 levels, consistent with a basal level of cellular stress. Other Hsp70 
family members include Grp75 (HSPA9; mortalin), which is expressed in the 
mitochondria. Recently, Grp75 has also been found in the cytosol and proposed to play 
an important cytoplasmic role in cancer (76, 77). In the endoplasmic reticulum, Grp78 
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(HSPA5; BiP) plays roles in proteostasis of the secretion system (78), which is 
especially important in leukemia cells that have active secretion systems. Seminal 
studies in the Workman laboratory have shown that siRNA knockdowns of both Hsc70 
and Hsp70 are required to arrest tumor cell growth (72). Likewise, Grp75 has been 
implicated in preventing apoptosis and senescence in MCF7, U2OS, and COS7 cells 
(79, 80). It isn’t yet clear which Hsp70s might be the best targets for anti-cancer 
therapy. Moreover, discriminating between the family members with small molecules 
might be difficult, as they are highly conserved (~50% identical). However, differences in 
their subcellular localization or the identity of their co-chaperones might eventually be 
used to focus inhibitors on specific family members. This approach will be discussed in 
more detail in Chapter 4. 
 
1.4.1 Evidence Linking Hsp70 to Cancer 
 Hsp70 levels are constitutively elevated in both solid and liquid tumors when 
compared to normal or immortalized cells (81, 82). Further, its expression levels 
correlate with disease progression in multiple cancers (83) and Hsp70 expression 
directly predicts resistance to an array of chemotherapeutics, radiation therapies (3, 5, 
6, 72, 84) and immune-mediated destruction of cancer cell (85, 86). These observations 
have driven interest in better understanding the roles of Hsp70 in cancer and exploring 
this chaperone as a potential drug target. 
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 The expression of Hsp70 in such a diverse set of tumors suggests that it may act 
more broadly towards oncogenic proliferation instead of modulating only a single 
pathway. Indeed, Hsp70 binds c-jun (JNK) (87), APAF-1 (88), and AIF (89), inhibiting 
the formation of the death-inducing signaling complex (90); it also prevents Bcl-2 
translocation to the mitochondria (91, 92) and prevents caspase-9 recruitment to the 
apoptosome (88) (Figure 1.2). Thus, Hsp70 is thought to guard against both extrinsic 
and intrinsic death triggers, as well as caspase-dependent and  -independent forms of 
apoptosis. Additionally, recent results suggest that Hsp70 inhibition might trigger 
necrosis (93), senescence (3, 6) and/or autophagic cell death (11). These observations 
support the notion that Hsp70 serves as a general hub of pro-survival activities and that 
11 
it might be a weak link in many cancers. In fact, a comparison between the pathways 
reported to be regulated by Hsp90 and those controlled by Hsp70 suggests that Hsp70 
may have an even broader role in cell survival (Figure 1.3). 
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1.5 Pharmacological Targeting of Hsp70 
 Despite its roles in governing the oncoproteome, no Hsp70 inhibitors are 
currently in clinical trials. However, several groups are working towards developing 
Hsp70-targeting molecules, and some of their efforts will be discussed here.  
 One emerging theme from this work is that the known Hsp70 inhibitors bind 
multiple sites that are dispersed across the protein surface (Figure 1.4). These sites are 
found in both the SBD and the NBD and the compounds include those that are 
competitive for ATP binding and those that bind a variety of allosteric sites. To organize 
this discussion, the various compounds will be categorized by their reported binding site 
and whether they are orthosteric or allosteric inhibitors. 
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1.5.1 Compounds that bind in the SBD of Hsp70 
 
1.5.1.1 PES (or PFTµ) 
 Originally discovered out of a screen for molecules that activate p53-mediated 
apoptosis, 2-phenylethynesulfonamide (PES or PFTµ) was found to interact with the 
SBD of Hsp70 (Figure 1.4) (11). A biotinylated version of PES binds Hsp70 in cell 
lysates, and specifically to the to the lid region of the SBD (aa 573-616), as measured 
by mass spectrometry. Further mutagenesis and docking studies suggest that the 
compound may bind in a helical bundle within the SBD’s lid (94). This region of Hsp70 
has relatively low conservation amongst Hsp70 family members and PES has been 
shown to bind Hsp72, but not Grp75/Mortalin or Grp78/BiP. 
 Analysis of PES-treated cell lysates showed that the compound disrupts binding 
of Hsp70 to p53, suggesting that some of the contacts between the chaperone and its 
clients may be disrupted by PES. Moreover, PES appears to block the interactions of 
Hsp70 with some of its co-chaperones, including CHIP, Hsp40 (DjB1), and Bag-1M. The 
structural basis of this effect on clients and co-chaperones is not yet clear. One 
possibility is that the compound disrupts the lid architecture, which might interrupt 
binding to some clients and TPR-domain co-chaperones, such as CHIP, which bind to 
the C-terminal EEVD motif. However, it is less clear why binding in the lid region would 
impact Hsp40 or BAG domain interactions, which are thought to occur far from that site 
(56, 59). It is possible that binding may allosterically regulate these distal protein-protein 
contacts. Another idea is that PES globally destabilizes Hsp70’s structural architecture, 
thereby disrupting its protein-protein interactions with all three classes of co-chaperones 
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and its clients. 
 PES-treated cells exhibit striking vacuolization of the cytosol, suggesting that the 
compound may impair lysosomal activity (11, 95). Further, PES elevates the levels of 
LC3-II in multiple cell lines, signifying increased autophagic flux. This activity appears to 
be particularly toxic to acute myeloid leukemia (AML) and acute lymphoblastoid 
leukemia (ALL) cells, suggesting that PES might be promising in the treatment of acute 
leukemias (96). 
 Based on the results with PES, a recent study explored synthetic analogs. PES is 
a simple, “fragment-like” molecule (Figure 1.4) with a high ligand efficiency (LE), which 
makes it an attractive scaffold for further elaboration. Interestingly, the derivation studies 
showed that the amide could be replaced with a pyrrolidine without a loss of activity, but 
that reducing the acetylene was not tolerated. From those studies, a derivative 
containing a chloro group at the meta-position of the benzyl moiety (2-(3-chlorophenyl) 
ethynesulfonamide; PES-Cl) was identified (94). This compound was more potent than 
PES in cell viability studies and appeared to share the other hallmarks of PES activity in 
cells (e.g. vacuolization, LC3-II accumulation). However, only a handful of PES analogs 
have been tested and detailed structure-activity relationships (SAR) have not emerged. 
Further, a recent manuscript calls into question whether PES acts through the Hsp70 
system (97). 
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1.5.1.2 ADD70 
 Hsp70 counters apoptotic death, in part, by interacting with apoptosis-inducing 
factor (AIF) and preventing its translocation from the mitochondria to the nucleus (98). 
Schmitt et al. used deletion mutants of AIF to map the precise region of AIF that binds 
Hsp70. They used this information to build a cytosolic AIF-mimetic, named ADD70, 
which competes with endogenous AIF for binding to Hsp70. Although the mimetic itself 
is not cytotoxic, ADD70 does sensitize cancer cells to staurosporine, vinblastine, and 
other therapeutics. Based on analogy with other Hsp70 clients, one might assume that 
AIF binds in the SBD of Hsp70s (Figure 1.4), however, this hypothesis has not been 
tested. Further, membrane-permeable, synthetic analogs haven’t yet been developed. 
 The lack of toxicity in response to ADD70 is interesting because most of the 
other molecules that bind Hsp70 are cytotoxic as stand-alone agents (see below). Thus, 
ADD70 may bind to the chaperone in a unique way, interrupting only select chaperone 
functions. Another possibility is that the region of ADD70 that binds Hsp70 is a hub for 
other protein-protein interactions. If this is the case, then the activity of ADD70 may be a 
function of multiple pathways, including Hsp70. Further mechanistic work will be 
required to address these issues.  
 One interesting clue to the function of ADD70 comes from studies on its 
treatment of immunocompetent mice. Although ADD70 was not inherently cytotoxic in 
immunodeficient mouse models, it decreased tumor growth in immunocompetent mice. 
Histological examinations confirmed infiltration of CD8+ cytotoxic T-cells in tumor cells 
expressing ADD70-GFP (98). Thus, ADD70 appears to enhance immunogenicity 
through an unknown mechanism.  
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1.5.1.3 Spergualin 
 The polyamine natural product, spergualin, was originally identified as a potent 
anti-bacterial agent with broad spectrum activity (99). Subsequent worked showed that 
this molecule also has anti-cancer and immunosuppressive activities (100-102). 
Synthetic efforts have removed some of the metabolic liabilities of spergualin, including 
the hydroxyl at carbon 15, which have greatly improved the physical properties of the 
chemical series (103, 104). The most advanced of the spergualin analogs, 15-deoxy-
spergualin (15-DSG) is clinically approved in Japan for the treatment of acute allograft 
rejection, making this molecule the lone Hsp70 inhibitor approved for human use (105, 
106).  
 15-DSG was found to be selective for Hsp70 in cells, using mass spectrometry 
and pull down studies (107, 108). Further, this compound was shown to bind to the C-
terminus of Hsp70s and chemically crosslink to the EEVD motif. As discussed above, 
this region of the SBD is interesting because it serves as a site for interactions with TPR 
domain co-chaperones. Thus, it is possible that spergualin analogs may disrupt co-
chaperone interactions, although this has not been shown. Further, there is not a crystal 
structure of 15-DSG bound to Hsp70, so the exact binding site is uncertain and SAR 
studies have not benefitted from structural knowledge.  
 Early SAR studies were focused on three key regions of 15-DSG, the central α-
hydroxyglycine core, the guanidylated fatty chain and the spermidine-derived 
polyamine. Nishizawa and co-workers replaced the central α-hydroxyglycine with 
various α- or ω-amino acids and the anti-tumor activities of these analogs were 
evaluated against L1210 (IMC) mouse leukemia cells (103). From the resulting SAR, 
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the authors concluded that the central α-hydroxyglycine could be replaced with either 
glycine or an L-serine residue. The authors also altered the length and flexibility of the 
guanidinoheptanoic acid region to study its role in anti-tumor activity. It was discovered 
that a 4-guandino-phenylbutyric acid shared similar anti-tumor activity with 15-DSG, 
suggesting that significant bulk could be tolerated in that region. Umeda and co-workers 
subsequently studied modifications of the spermidine moiety (109). The SAR concluded 
that both the primary and secondary amino groups were important for anti-tumor 
activities. Together, these studies have shown a relatively narrow SAR around 15-DSG.  
 Based on its success as an immunosuppressant, 15-DSG was explored as an 
anti-cancer agent in a Phase I clinical trial (80 and 2792 mg/m2/day) against refractory 
solid tumors in 56 patients (110). However, the average plasma concentration was only 
0.07 to 7 µg/mL, largely because of rapid clearance (terminal half-life of 1.9 hr). These 
concentrations are below the anti-tumor activity of the compounds in many cancer cell 
lines, suggesting that more potent and stable analogs are needed. Dose-limiting toxicity 
was reversible hypotension, which occurred in five of six patients with the highest 
dosage, but it isn’t clear whether this toxicity was on- or off-target. 
 The mechanism by which spergualin analogs activate cell death is not yet clear. 
Also, additional medicinal chemistry efforts will likely be required to improve the potency 
and stability of these molecules. However, the relative safety of 15-DSG in humans 
makes this scaffold an attractive option for further mechanistic studies. 
 
 
 
19 
1.5.2 Compounds that bind in the NBD of Hsp70 
 
1.5.2.1. ATP/ADP Competitive Inhibitors 
Hsp70 binds ATP with an affinity that is nearly 1000-fold tighter than binding of 
nucleotide to Hsp90 (49). As such, it is more difficult for compounds to compete with 
ATP in Hsp70’s nucleotide-binding pocket. These challenges have been nicely 
summarized by Massey, who compared the hit rates from fragment screens performed 
against multiple nucleotide-binding targets, including Hsp70 and Hsp90. This analysis 
showed that Hsp70 had a hit rate of only 0.4%, while Hsp90 had a hit rate of 4.4%. High 
hit rates are typically associated with better “druggability” and they have been shown to 
be a predictor of future success in fragment elaboration campaigns. Thus, Massey 
concluded that the ATP-binding site of Hsp70 is an unusually poor drug target, having 
one of the worst hit rates yet described. Further, the ATP-binding cassette in Hsp70 is 
highly conserved amongst several abundant proteins, such as actin and hexokinase. 
Thus, it is predicted to be difficult to selectively inhibit Hsp70 by this approach. 
Despite these issues, a number of competitive inhibitors have been reported to 
bind in the ATP-binding cassette of Hsp70s (Figure 1.4) and these have been found to 
have anti-tumor activity. Before discussions of allosteric inhibitors, it may be illuminating 
to examine these efforts in more detail. 
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1.5.2.1.1 Apoptozole 
 Apoptozole was discovered in a screen of imidazoles that trigger apoptosis (111). 
A resin-linked version of apoptozole was used to show that the compound binds to the 
NBDs of both Hsc70 and Hsp72, and a fluorescent version of the molecule co-localized 
with anti-Hsp70 antibodies in cells. Using an analog of apoptozole with an installed 
electrophile, the binding site of the compound was further mapped in vitro to a region 
near the nucleotide-binding pocket (112). Using this distance constraint, computational 
modeling results suggested that the compound might compete with nucleotide. 
Consistent with this model, apoptozole mildly inhibits the ATPase activity of Hsp70 
(~60% reduction in ATPase rate at 200 µM). However, verification of this binding site by 
formal competition studies and/or structural studies has not been reported. 
 
1.5.2.1.2 VER-155008 
 In a rational approach, Williamson, Massey and co-workers developed a 
collection of adenosine analogs and screened them in a fluorescence polarization (FP) 
assay for binding to Hsp70. This process yielded multiple analogs with IC50 values in the 
low micromolar range. Co-crystallization confirmed that two of these molecules bind in 
the ATP-binding cleft. From this starting point, analogs were developed and the most 
potent of these compounds, VER-155008, had an IC50 value of 0.5 µM. This compound 
also had promising anti-proliferative activity in HCT116 cells, with an EC50 of 5 µM, and 
it destabilized some of the expected client proteins, including Raf1 and Her2 (113). 
Subsequent work showed that VER-155008 induced both caspase-dependent and -
independent apoptosis in colon carcinoma cells (70). These studies have demonstrated 
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that inhibitors can be developed starting from structural knowledge of the Hsp70 
nucleotide-binding site. 
 In a recent study, the same team has reported the development of new inhibitors 
of Grp78, the ER-resident Hsp70 family member. Starting with the BAG1-Hsc70 crystal 
structure, they designed adenosine-mimetics that are selective for Grp78 over Hsc70 
(114). Co-crystal structures suggest that polar groups appended to the ribose ring of 
VER-155008 disfavor binding to Grp78, which has an isoleucine residue rather than a 
polar threonine in the key amino acid 37. Consistent with this idea, VER-155008, which 
has a hydrophobic cyano-benzyl group in that position, was not selective for any 
specific Hsp70 family member; in fact, its anti-proliferative activity likely comes from 
pan-inhibition of Hsp70s. 
 
 The next step in the development of these compounds is to understand whether 
they selectively bind to Hsp70 in cells, and if any differences in activity are observed in 
cancer cells compared to healthy ones. Further, it will be interesting to understand why 
competitive binding leads to client degradation. Is the inability of Hsp70 to actively cycle 
ATP/ADP linked to client turnover? Does the compound trap a specific state of Hsp70 
that is linked to the degradation pathways? In the toolbox of available Hsp70 inhibitors, 
active-site competitors will likely serve an important role. 
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1.5.2.2. Allosteric Modulators 
 One promising way to inhibit Hsp70’s activity in cancer cells may be to target 
molecules to the chaperone’s many allosteric sites (115, 116). This approach might be 
expected to avoid some of the problems associated with active-site inhibitors, including 
selectively targeting an ATP-binding fold that is highly conserved amongst many 
proteins. Another potential advantage of targeting allosteric sites is that Hsp70 
cooperates with a large number of important co-chaperones. Many allosteric sites in 
Hsp70 are located at sites of binding to co-chaperones (see Figure 1.1). Thus, 
molecules that bind allosteric sites might have profound effects on recruitment of co-
chaperones and might be more specific to cancer cells, where chaperones exist 
predominately in super complexes.  
 
1.5.2.2.1 MAL3-101 
 Members of the Hsp40 family of co-chaperones are critical regulators of Hsp70 
(56, 59, 60). Using a screen for modulators of Hsp70’s ATPase activity, Fewell et al. 
discovered MAL3-101, a dihydropyrimidine that inhibits Hsp40-enhanced ATPase 
activity without affecting Hsp70’s endogenous functions (117). Subsequent work 
showed that analogs of MAL3-101 bind at the interface of the Hsp70-Hsp40 complex 
and regulate formation of this heterodimer (118) (Figure 1.4). The binding site of the 
dihydropyrimidines is well conserved and members of this chemical series have activity 
against multiple human, yeast and prokaryotic Hsp70s (119-121).  
 The ER resident Hsp70, BiP, collaborates with a series of Hsp40s to coordinate 
quality control in this organelle (122-124). Because BIP-Hsp40 pairs regulate secretion 
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of properly folded immunoglobulins (78), MAL3-101 was tested in a multiple myeloma 
model and it was found to exhibit anti-proliferative activity both in vitro and in vivo. 
Moreover, MAL3-101 was synergistic with the Hsp90 inhibitor, 17-AAG, and the 
proteasome inhibitor, MG-132 (125). These results suggest that inhibition of the Hsp70-
Hsp40 pair is a viable way to interrupt chaperone functions and induce apoptosis in 
cancer cells. This finding is important because the dihydropyrimidines have little activity 
against isolated Hsp70, so their anti-proliferative activity likely originates from activity 
against the Hsp70-Hsp40 complex rather than the chaperone alone. The next steps in 
the development of this chemical series are to improve the affinity and potency of the 
compounds. 
 
1.5.2.2.2 MKT-077 
 MKT-077 was first synthesized as rhodacyanine dye by Fuji Film and it was 
subsequently shown to have potent activity against multiple cancer cell lines (126-128). 
Interestingly, this compound had little toxicity against either fibroblasts or immortalized 
epithelial lines. This discrimination led to the testing of MKT-077 in Phase 1 clinical trials 
(129). The trial was halted due to renal magnesium wasting; however, enthusiasm for 
this chemical series remains strong and it represents one of the few Hsp70 inhibitors to 
advance to clinical trials.  
 MKT-077 exerts its anti-cancer activity by binding to Hsp70 (80). Specifically, 
NMR and docking studies have shown that the compound binds to a conserved 
allosteric pocket at the junction between subdomains IA and IIA of the NBD (130) 
(Figure 1.5.A). Although this pocket is adjacent to the ATP-binding cleft, MKT-077 
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analogs do not compete for binding to nucleotide. Rather, binding of MKT-077 appears 
to trap the chaperone in the ADP conformation (79, 130), limiting client release (131) 
(Figure 1.5.B). Consistent with this idea, MKT-077 stabilizes binding of Hsp70 to model 
substrates in vitro (132, 133). While tighter binding of Hsp90 to clients might be 
expected to be protective, tighter binding of Hsp70 appears to destabilize Hsp70 clients, 
such as Akt (134). One possible mechanism for this activity is that prolonged dwell time 
of Hsp70 on clients may recruit effectors of the ubiquitin-proteasome system (135). 
Consistent with this idea, work in the nuclear hormone receptor system has suggested 
that Hsp70 is linked to client degradation, while Hsp90 is generally protective (136).  
 The mechanism by which MKT-077 and its analogs suppress growth of cancer 
cells is not yet clear. MKT-077 and its analogs appear to trigger apoptosis, as judged by 
microscopy and their effects on apoptotic clients (80, 137). However, Hsp70 has been 
implicated in senescence (3, 6, 79), cell cycle arrest (138, 139), and even necrosis (93). 
The exact mechanisms, their relative importance and the molecular details of the 
pathways have not been identified. In Chapters 2 - 4, I describe efforts towards 
developing more potent MKT-077 analogs and using them as probes to clarify these 
issues for the first time. The MKT-077 scaffold was chosen for this effort because it has 
the best-characterized binding site on Hsp70s and it has the most compelling selectivity 
in cells, compared to other Hsp70 inhibitors. Thus, we considered it the most promising 
scaffold for building the first chemical probes for this chaperone. 
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1.6 Combination Warfare 
 Most current chemotherapeutic regimens contain some permutation of 
vinblastine, cisplatin, methotrexate, prednisone, adriamycin, and any of several other 
cytotoxic drugs. Cocktails of these active agents are used to maximize therapeutic 
efficacy, while reducing toxicity, side effects and resistance. In this context, it is worth 
discussing how Hsp70 inhibitors, such as the ones reviewed here, might be used in 
rational combination with other compounds.  
 As described earlier, Hsp90 acts as a central hub in cancer cells, directing the 
fates of hundreds of signaling effectors (12, 34, 35). Thus, combining Hsp90 inhibitors 
with inhibitors of other pathways would be expected to be synergistic. Indeed, 
combining Hsp90 inhibitors with conventional chemotherapeutics or radiation therapy 
creates powerful regimens (140-142). Further, Hsp90 inhibitors have been shown to 
restore sensitivity in cell lines previously resistant to drugs such as tamoxifen, 
doxorubicin, or trastuzumab (40, 143, 144). Similarly, the idea of combining an Hsp90 
inhibitor with a drug targeting Hsp70 has been suggested by many groups (10, 73). 
Hsp70’s induction upon HSF1 release makes it an ideal target to complement Hsp90-
mediated therapy. In fact, synergy has been later observed between Hsp90 inhibitors 
and either VER-155008 or MAL3-101 (70, 125, 145). 
 Another interesting combination approach may be to combine Hsp70 inhibitors 
with different mechanisms-of-action. As discussed above, targeting different sites on 
Hsp70 produces non-redundant outcomes. For example, ADD70 sensitizes cells while 
PES, VER-155008, and MKT-077 are actively cytotoxic. Thus combinations of these 
compounds might be expected to be synergistic. Further, compounds such as MAL3-
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101 that target the Hsp70-Hsp40 complex might be synergistic with compounds that 
target other regions. In this way, the Hsp70 complex itself might provide a rich source of 
novel combinations. In Chapters 3 and 4, I explore these ideas using more potent, 
selective, and stable derivatives of MKT-077. 
 
1.7 Conclusions and Future Directions 
 Cancer cells must cope with the stress of rapid division and high mutational 
rates, ultimately becoming “addicted” to chaperones. Thus, proteins within the protein 
quality control system, such as molecular chaperones, have become desirable drug 
targets. Inhibition of these systems is thought to disrupt multiple anti-death pathways at 
once (12, 146, 147), providing a powerful disruption of central signaling hubs. 
 In this backdrop, genetic studies have strongly implicated Hsp70 as a particularly 
good anti-cancer target, either as a stand-alone target or as a target that might impact 
resistance to other chemotherapeutics. (41-43). However, the suitability of Hsp70 as a 
drug target remains somewhat of an enigma. Part of the difficulty of “inhibiting” this 
system is that it isn’t yet clear what inhibition means or whether all types of inhibition will 
yield the same outcomes. As mentioned above, one goal might be to stabilize Hsp70 
interactions with clients, potentially by targeting allostery in the chaperone. Hsp70 
undergoes a complex series of dynamic conformational changes and engages in 
multiple protein-protein interactions with co-chaperones and client proteins. Further, it 
has broad cellular activity in protein folding, disaggregation, the assembly of multi-
protein complexes, subcellular trafficking, protein turnover, antigen presentation and 
transcription (148-151).  Current models suggest that these varied chaperone activities 
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arise from unique combinations of Hsp70 family members and their co-chaperones. 
Thus, the desired Hsp70 “target” may actually be a specific set of multiple proteins. This 
idea is illustrated by MAL3-101, which inhibits the Hsp70-Hsp40 combination (117, 
118). 
 As this field develops, it will be interesting to know whether all types of inhibitors 
cause destabilization of oncogenic clients, as is the case for Hsp90 inhibitors. However, 
current data with compounds such as ADD70 suggest that Hsp70 may be a different 
type of target. We propose that each type of Hsp70 “inhibitor” might have unique 
capabilities, depending on what types of allosteric programs it interacts with. Thus, the 
suite of Hsp70 inhibitors is likely to include numerous molecules with non-redundant 
mechanisms of action. 
 To this end, emerging data suggests that Hsp70 may not be acting purely to 
oppose apoptosis, but more generally as a pro-survival factor, acting as a “back-up” to 
Hsp90 in maintaining the oncogenic proteome. Thus, the combination of Hsp70 
inhibitors with molecules targeting Hsp90, the proteasome, and other protein quality 
control pathways promises to be a powerful approach towards safer and more effective 
chemotherapeutic regimens.  
 In this dissertation, several of these key questions are addressed. In Chapter 2, I 
describe the development of more potent and stable Hsp70 inhibitors, improving on the 
MKT-077 scaffold. In Chapters 3 and 4, I use these tool compounds to reveal the roles 
Hsp70 plays in maintaining the cancer phenotype. Finally, in Chapter 5, I discuss future 
studies to explore Hsp70 as a hub of cancer cell signaling, and the impact of adding 
these inhibitors to chemotherapeutic regimens. 
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Notes 
This work has been, in part, submitted as an invited review to Current Topics in 
Medicinal Chemistry entitled “Allosteric Inhibitors of Hsp70: Drugging the Second 
Chaperone of Tumorigenesis.” Sharan R Srinivasan, Xiaokai Li, and Jason E. Gestwicki 
contributed intellectually to this review.  
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Chapter 2 
 
Development of a Tool to Probe Hsp70 Function: Synthetic Derivatives of the 
Allosteric Modulator, MKT-077. 
 
2.1 Abstract 
The rhodacyanine, MKT-077, has anti-proliferative activity against cancer cell 
lines through its ability to inhibit members of the heat shock protein 70 (Hsp70) family of 
molecular chaperones. However, MKT-077 is rapidly metabolized (t1/2 < 5 min) and is 
only moderately efficacious (EC50 ~ 2 µM), which limits its use as either a chemical 
probe or potential therapeutic. In this chapter, we report the design, synthesis and 
characterization of MKT-077 analogs. This work resulted in compound 30 (JG-98), a 
derivative with an improved microsomal half-life (t1/2 = 37 min) and increased potency 
against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 values of 0.4 ± 0.03 
µM and 0.7 ± 0.2, respectively). Additionally, JG-98 bound Hsc70 in vitro with an affinity 
over 60 times that of MKT-077 and NMR titration experiments confirmed that JG-98 
binds to the conserved allosteric site on Hsp70. These studies advance MKT-077 
analogs as the first chemical probes for studying Hsp70’s roles in cancer (described in 
Chapters 3 and 4). 
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2.2 Introduction 
 
2.2.1 Targeting Hsp70 in Cancer 
As outlined in Chapter 1, heat shock protein 70 (Hsp70) is an ATP-dependent 
molecular chaperone that plays essential roles in protein homeostasis (1, 2). There are 
thirteen members of the Hsp70 family in mammals (3), including the constitutively 
expressed, cytosolic heat shock cognate 70 (Hsc70, HSPA8), the stress-inducible, 
cytoplasmic heat shock protein 70 (Hsp72, HSPA1) and the mitochondrial Hsp70 
(mtHsp70, mot-2, HSPA9). These chaperones bind and stabilize a wide array of 
proteins, including many kinases and transcription factors involved in pro-survival 
signaling (2, 4, 5). Accordingly, high levels of Hsp70 activity are associated with 
immortalized cells and poor prognosis in multiple types of cancer, including breast 
cancer, endometrial cancer and cervical cancer (6). Many cancer cells appear to 
become “addicted” to these high chaperone levels and activity, as dual silencing of 
Hsc70 and Hsp72 leads to cell death only in tumor cells, but not normal fibroblasts (7). 
For these reasons, Hsp70 has emerged as a potential target for anti-cancer agents (1). 
Inhibition of Hsp70s might be especially powerful in combination with other 
chemotherapies because the levels of Hsp72 are dramatically increased after exposure 
to other therapies, such as Hsp90 inhibitors (8), proteasome inhibitors (9), and radiation 
(10). However, small molecules targeting Hsp70 have lagged in development, in part, 
due to its high affinity for ATP (11), making inhibitors against this pocket lackluster. As 
such, we have decided to pursue an alternative strategy.  
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2.2.2 MKT-077: Allosteric Inhibitor of Hsp70 
MKT-077 is a cationic rhodacyanine that was originally developed as a dye and 
later found to have promising anti-proliferative activity against numerous cancer cell 
lines, including those derived from bladder carcinomas, colon carcinomas, breast 
carcinomas, melanomas, and pancreatic carcinomas (12-14). This activity led MKT-077 
to be advanced to Phase I clinical trials against solid tumors. However, it was 
abandoned due to renal toxicity, specifically magnesium wasting (15). More recently, 
Wadhwa and colleagues revisited the scaffold and used a biotinylated version of MKT-
077 to show that this compound derives its anti-cancer activity by binding to members of 
the Hsp70 family, including Hsc70 and mtHsp70 (14, 16, 17). Subsequent work showed 
that a portion of the anti-proliferative activity of MKT-077 involved release of the tumor 
suppressor, p53, from mtHsp70 (14). Recently, we used NMR to discover that MKT-077 
binds Hsc70 at an allosteric site within the nucleotide-binding domain (NBD) (18). 
Interestingly, this site is conserved in the major Hsp70 family members, including Hsp72 
and mtHsp70, and it appears to be important in the chaperone’s ATP hydrolysis cycle 
because an analog of MKT-077, YM-01, disrupts nucleotide turnover (16, 18). 
Treatment with YM-01 leads to degradation of the chaperone “client” Akt1 in tamoxifen-
resistant MCF7 breast cancer cells (19), suggesting that binding to this allosteric site 
also disrupts the cellular functions of Hsp70s, at least in cancer cells. However, MKT-
077 and YM-01 are not toxic to fibroblasts or normal epithelial cells (20). Thus, MKT-
077 only appears to be toxic to the cells that are “addicted” to elevated levels and 
activity of chaperones, reminiscent of the mechanisms that are commonly invoked for 
Hsp90 and proteasome inhibitors (21, 22). Unfortunately, MKT-077’s rapid metabolism 
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has limited its use, making it difficult to employ as a tool compound in cells or animals. 
Here we describe efforts to improve upon MKT-077 to develop a tool compound to 
probe Hsp70’s oncogenic activity. 
 
2.3 Results and Discussion 
To better understand MKT-077 metabolism, our group first incubated a close 
analog, YM-01, with mouse liver microsomes and confirmed that it is susceptible to 
rapid metabolism, with a lifetime of only 4.4 ± 1.0 min (23).  LC-MS/MS analysis of the 
treated YM-01 revealed that the benzothiazole and pyridinium rings were the major sites 
of P450 oxidation (24) (Figure 2.1).  
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2.3.1 General Synthetic Approach 
Guided by those studies, a postdoctoral fellow in the group, Xiaokai Li, used a 
previously reported synthetic route (Scheme 2.1) (16) to generate MKT-077 analogs 
that are designed to remove these metabolic liabilities. Briefly, the syntheses started 
with cyclization of substituted anilines with potassium ethyl xanthate, followed by 
methylation of the cyclized products by iodomethane under mild basic conditions. The 
resulting benzothiazoles were activated by methyl p-toluenesulfonate, and coupled with 
a series of N-substituted rhodanines. These products were methylated by methyl p-
toluenesulfonate, followed by another coupling with an activated heterocycle. The 
products were dissolved in methanol and passed through a chloride exchange column 
to generate the final compounds 1-31 in overall yields between 20% and 40% (Table 
2.1).  
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2.3.2 Substitutions on the Benzothiazole Ring Improve Metabolic Stability 
To find an analog of MKT-077 with better potential as a chemical probe for 
studying Hsp70’s roles in cancer, MKT-077, YM-01 and compounds 1-31 were 
evaluated for anti-proliferative activity in MDA-MB-231 and MCF7 breast cancer cells 
using MTT assays (25). In addition, their activity against normal mouse embryonic 
fibroblasts (MEFs) was also measured. We would expect that a useful MKT-077 analog 
would be less toxic to untransformed cells. Similarly, the stability of the compounds in 
the presence of mouse liver microsomes was recorded to identify analogs more stable 
than MKT-077. 
Using these tests, MKT-077 had EC50 values of 1.4 ± 0.2 µM and 2.2 ± 0.2 µM 
against the breast cancer cells (Table 2.1). YM-01, which differs from MKT-077 only in 
the methyl substitution in the R3 position, was only slightly weaker (EC50 values of 2.0 ± 
0.2 and 5.2 ± 0.8 µM). Consistent with the literature, neither molecule was toxic to MEFs 
(EC50 > 50 µM) and both had short half-lives in microsomes (t1/2 < 5 min). Guided by the 
earlier metabolic studies (Figure 2.1), we found introducing a fluorine in the 3, 4, 5 or 6 
positions of the benzothiazole (R1) of YM-01 (compounds 1-4) significantly improved 
stability as measured by liver microsomes (t1/2 = 15, 23, 7.7 and 16 min, respectively). 
However, these substitutions also reduced potency (EC50 values between 2.2 and 18 
µM). When the same fluorinations were introduced in the context of the ethyl 
modification at the R3 position (compound 5-8), potency was only slightly improved 
(EC50 between 0.8 and 13 µM). Replacing fluorines for chlorines in the YM-01 scaffold 
(compounds 9-12) did not improve potency and, in fact, further increased the EC50 
values to between 4.1 and 28 µM. Similarly, placing trifluoromethyl or methoxy groups 
43 
at positions 4’ and 5’ (compounds 13-16) decreased activity to between 3 and more 
than 30 µM (Table 2.1). Together, these results suggested that electrophilic 
substitutions on the benzothiazole protected against metabolism, but only smaller 
moieties were tolerated. Larger groups reduced anti-proliferative activity, likely due to 
steric constraints imposed on the benzothiazole ring by the binding pocket of Hsp70 
(see below). 
 
2.3.3 Hydrophobic Functionalization of the Pyridinium Ring Improves Potency 
In an attempt to increase the potency of this series, we made substitutions at the 
central rhodanine ring (R2) and the N-substitutions of the pyridinium (R3). Replacing the 
R2 ethyl group of MKT-077 with an allyl or benzyl group (compounds 17 and 18) did not 
substantially affect activity against either cell line. Likewise, replacing the ethyl moiety of 
the pyridinium (R3) with a propyl group (compound 19) did not significantly improve 
potency (EC50 values 2.8 ± 0.8 and 1.6 ± 0.2 µM against MCF7 and MDA-MB-231 cells, 
respectively). However, increasing the size of this substituent to a benzyl group 
(compound 20) improved activity by approximately 2-fold (EC50 values of 1.5 ± 0.2 and 
1.0 ± 0.2 µM). The more hydrophilic 2-hydroxyethyl (compound 21) decreased potency 
(EC50 values 6.9 ± 2.1 and 24 ± 3.3 µM), suggesting that hydrophobic groups were 
favored in this position. 
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2.3.4 Thiazolium Ring is More Potent than Pyridinium 
Next, we made modifications to the pyridinium heterocycle (Hy). Changing the 
position of the heteroatom in the pyridinium from the 2 to 4 position (compound 22) did 
not significantly influence anti-proliferative activity in MDA-MB-231 cells (EC50 1.7 ± 0.1 
µM), while the activity was reduced in MCF-7 cells (EC50 19 ± 4.9 µM). Similarly, adding 
another nitrogen to the ring (compound 23) reduced potency by approximately 2-fold, 
while replacing the pyridinium with a thiazolium (compound 24) improved the potency by 
3-fold in MCF-7 cells (EC50 0.7 ± 0.1 µM) and slightly reduced activity in MDA-MB-231 
cells (EC50 5.1 ± 0.3 µM). To test whether the improvement in activity by the 2-thiazolyl 
group at R3 would be robust, we also generated analogs with this modification in the 
context of ethyl and benzyl substitutions at R3 (compounds 25 and 26, respectively). 
These compounds followed the structure-activity trends of the earlier molecules, with 
the cytotoxicity of compound 26 improved by 2-fold in MDA-MB-231 cells and 4-fold in 
MCF7 cells, with EC50 of 0.5 ± 0.1 and 0.6 ± 0.04 respectively. 
 
2.3.5 JG-98, an Improved MKT-077 Analog that Incorporates the Initial Structure-
Activity Relationships 
Together, these results suggested that a modest increase in anti-proliferative 
potency might be gained by switching the pyridinium for a thiazolium, and that 
appending a benzyl moiety to this ring might further promote activity. Combining these 
features with halogen replacements on the benzothiazole ring resulted in compounds 
27-31. As halogenation of the benzothiazole ring at the 5’ position had proven most 
effective, compound 30 (JG-98) was taken forward for further studies. 
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2.3.5.1 JG-98 Has Improved Metabolic Stability in vitro and in vivo 
To confirm that combining the above-described structural changes led to an 
improved oxidative stability, we analyzed compound metabolism in liver microsomes. 
We found that JG-98 had a lifetime of 37 min, which is at least 7-fold better than MKT-
077 or YM-01 (Figure 2.2.A).  JG-84 was not significantly more stable than YM-01 (t1/2 = 
8 min), further confirming that halogenation of the 5’ position on the benzothiazole ring 
was important.  
In collaboration with Duxin Sun (University of Michigan), we also examined JG-
98’s stability in vivo by performing intraperitoneal injections of CD-1 mice and 
measuring drug levels in the blood stream (Figure 2.2.B). Despite a poor oral 
bioavailability, JG-98 displayed favorable pharmacokinetics in vivo (t1/2 = 17 hrs), 
warranting further investigation. 
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2.3.5.2 JG-98 Interacts with Hsp70  
 
2.3.5.2.1 JG-98 Binds Tightly to Hsc70 in vitro 
Next, we wanted to explore whether JG-98 retained binding to Hsc70 in vitro. To 
test this idea, we synthesized a biotinylated version of JG-98, using a modification of the 
previous synthetic route (Appendix 2.1.A). Using a previously reported ELISA procedure 
(16), the affinity (KD) of JG98-biotin for purified, human Hsc70 was calculated to be 87 ± 
16 nM (Figure 2.3), which was ~60 times improved over the affinity of Hsc70 for a 
biotinylated version of MKT-077 (KD = 5.8 ± 0.77 µM). Thus, the chemical modifications 
leading to JG-98 not only improve its metabolic stability, but also dramatically increase 
its affinity for binding to Hsp70 in vitro. 
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2.3.5.2.2 NMR Spectroscopy Reveals Binding Site of JG-98 
Our group had previously found that MKT-077 binds to an allosteric site on 
Hsc70, which is not overlapping with the ATP-binding cleft (26). To determine if JG-98 
shared this binding site, it was titrated into an aqueous solution of 15N-labeled DnaK 
nucleotide binding domain (DnaK1-388) and its interactions with the protein monitored by 
NMR. We used DnaK, a prokaryotic ortholog of Hsp70 (27), in these studies because of 
its good behavior in solution and the availability of a large number of NMR resonance 
assignments (27). Titrating JG-98 (200 µM) into the NBD of 1H-15N DnaK1-388 (160 µM) 
showed strong chemical shifts (ΔHz > 30) in the TROSY-HSQC experiment. Strong 
shifts appeared in a deep, hydrophobic pocket formed by Ile142, Phe148 and other 
residues (Figure 2.4.A) and additional shifts were seen in nearby surface residues: 
Gly222, Asp223, and Thr224. A similar region was previously implicated in the binding 
of MKT-077 to Hsc70 (18) and an overlay of the two sets of compound-sensitive 
residues suggested that MKT-077 and JG-98 interact with the chaperone at the same 
site (Figure 2.4.B).  
The major sites perturbed by JG-98 (residues I142, F148, D222, T223, H224) are 
highly conserved amongst prokaryotic and eukaryotic Hsp70s. To this point, Dr. Xiaokai 
Li has recently shown that JG-98 has nearly equal affinity for E. coli DnaK and human 
Hsc70 (personal conversation). These perturbed residues are also nearly invariant in 
the major human family members, such as Hsc70 (HSPA8), Hsp72 (HSPA1A) and 
mtHsp70 (HSPA9) (Figure 2.4.C). Thus, compounds of this class will likely have affinity 
for nearly all of the family members, as previously suggested (18).  
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2.3.5.2.3 Docking of MKT-077 Analogs Unveils Structure-Activity Relationship 
Despite interacting with Hsp70 at a similar site, JG-98 displays significantly 
increased binding affinity over MKT-077. To understand this, we used molecular 
modeling and docking to examine the conformational orientation of MKT-077 and select 
analogs (Figure 2.5). All analogs appear to bind to Hsp70 in a “benzothiazole-in” 
position. However, larger groups, like the trifluoromethyl moiety on JG-48, appear to 
prevent proper interaction of compound with the pocket (Figure 2.5.C). This is 
consistent with the decreased activity shown for these compounds (Table 2.1). 
Reduction to a smaller halogen functionalization of the benzothiazole ring allowed JG-
98 to fit into the conserved pocket, though with a slightly offset orientation compared to 
MKT-077. The additional benzyl group off the thiazole ring also allowed for increased 
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hydrophobic contact with the chaperone surface, contributing to the increased binding 
affinity (Figure 2.5.D). 
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2.3.5.3 JG-98 Exhibits Improved Cytotoxicity Against Breast Cancer Cells 
To determine whether JG-98’s improved metabolic stability and affinity for 
binding Hsp70 in vitro resulted in increased cytotoxicity, we treated MCF-7 and MDA-
MB-231 cells and examined viability by the MTT assay. JG-98 exhibited significantly 
improved cytotoxicity against both cell lines (EC50 = 0.7 ± 0.2 µM and 0.4 ± 0.03 µM 
respectively) (Figures 2.6.A and B). JG-98 had increased activity against MEFs 
compared to MKT-077, but the selectivity for cancer cells was still estimated to be 
between 20- and 50-fold, well within the therapeutic index range for most 
chemotherapeutic agents (Figure 2.6.C).  
53 
 
 
54 
2.3.6 JG-98 Disrupts Hsp70’s Cooperation with Co-chaperones 
Hsp70 is a multi-functional chaperone required for many aspects of a protein’s 
life-cycle, including folding, trafficking, and degradation (28-31). To reduce its 
promiscuity and “fine-tune” its activity, Hsp70 is modulated by a class of proteins known 
as co-chaperones. These combinatorial complexes are thought to dictate the effect 
Hsp70 exerts on its client substrate (32-36). Further, these complexes are enriched in 
cancer cells to accommodate the need for increased proteostasis regulation (37), and 
are a potential target for selective drugging of Hsp70 activity in cancer cells. 
To examine whether JG-98 inhibited Hsp70 by disrupting these interactions, we 
analyzed ATPase rate, a functional read-out of Hsp70 activity. We found that JG-98 had 
no effect on Hsp70’s intrinsic activity (Figure 2.7.A), but significantly inhibited stimulation 
of Hsp70 ATPase rate by J-proteins, a class of Hsp70 co-chaperones (Figure 2.7.B).  
MKT-077 analogs stall ATP cycling in Hsp70 by stabilizing the ADP-bound state 
(26, 38), leading Hsp70 to bind tightly to its peptide substrates. Another student in the 
Gestwicki Lab, Jenny Rauch, has recently shown that the ADP conformation has a 
decreased affinity for nucleotide exchange factor (NEF) co-chaperones (39). 
Accordingly, we find that JG-98, which traps Hsp70 in an ADP-conformation, reduces 
the interaction between Hsp70 and Bag3, a NEF co-chaperone, by both flow cytometry 
and co-immunoprecipitation (Figures 2.7.C and D). 
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The ADP conformation of Hsp70 has a high affinity for both substrate as well as 
another co-chaperone, CHIP (C-terminal Hsp Interacting Protein), an E3 Ubiquitin 
Ligase. This increased Hsp70-CHIP interaction is thought to facilitate the degradation of 
Hsp70 client proteins via the proteasome (40, 41). This mechanism for MKT-077 
derivatives such as JG-98, in comparison to the ATP-competitive compounds (42, 43), 
leads to a highly effective and selective disruption of Hsp70’s oncogenic activities with 
limited toxicity. 
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2.4 Conclusions 
MKT-077 had previously shown promise as an allosteric inhibitor of Hsp70. 
However, metabolic instability and relatively modest potency limited its use. In this 
Chapter, a library of MKT-077 derivatives was synthesized to identify a more stable and 
potent analog. Compared to either MKT-077 or YM-01, the most promising compounds, 
such as 30 (JG-98) had improved potencies against breast cancer cells and extended 
lifetimes in liver microsome studies. Further, JG-98 bound to a conserved, allosteric site 
on Hsp70 with tight affinity. Dr. Xiaokai Li is using knowledge of the binding site and 
structure-activity relationships (SAR) in continuing efforts to generate more potent MKT-
077 analogs. Recent compounds from that effort have EC50 values of ~70 nM (Li, X., 
unpublished work), suggesting that the allosteric pocket is amenable to tight binding, 
potent compounds. 
Mechanistic studies suggest that JG-98 “traps” the ADP-bound state, decreases 
affinity for NEFs and interrupts the ATPase cycle. The resultant ADP conformation has 
a high affinity for substrate, furthering the idea that Hsp70’s domains can be modulated 
using allosteric perturbations. Zapporah Young, another student in the Gestwicki lab, 
has shown that MKT-077 derivatives not only increase Hsp70’s affinity for binding 
substrate in an in vitro ELISA platform, but also diminish the refolding capacity (Young, 
Z. et al, unpublished work).  
Although inhibition of a central member of the protein-folding machinery might 
appear an overly toxic strategy, seminal work has shown that knockdown of Hsp70 
isoforms is toxic to cancer cells only (44). Further, Hsp72-/- mice are viable, though 
sterile (45). Lastly, our lab in conjunction with the Dickey lab at USF, has shown that 
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MKT-077 derivatives are toxic only to cancer cells (19). Thus, drugging Hsp70 family 
members as anti-cancer therapies is a validated strategy, although uncertainty remains 
regarding the specific isoforms that should be targeted. 
While it is largely thought that Hsp72, the stress-inducible isoform, is the key 
target, previous studies in the Workman lab have shown that knockdown of both Hsc70 
and Hsp72 is crucial to cancer cell death (44). Our own work shows that MKT-077 
derivatives act on both Hsc70 and Hsp72 in vitro and in cellulo (Figures 2.3, 2.7 and 
Appendix 2.1). Given the conservation of the binding site for these compounds, it is 
likely that activity extends to other Hsp70 isoforms as well. Indeed, Wadhwa et al. 
showed that MKT-077 bound both Hsc70 and mtHsp70 (Grp75). To corroborate this, in 
collaboration with the Weissman Laboratory at UCSF, using a genomic shRNA screen 
(46), we have shown that our new derivatives exhibit a preferential dependence on 
mtHsp70 (Appendix 2.2), though its actions on cytosolic isoforms remain clear. 
Together, these studies advance the rhodacyanines as potential anti-cancer 
agents and improve their utility as chemical probes for studying Hsp70’s roles in cancer. 
This is an important advance for my thesis work, because it provides the first well-
characterized probe of Hsp70. Accordingly, JG-98 and a neutral derivative of MKT-077 
will be used in Chapters 3 and 4 to better understand the roles of Hsp70 family 
members in cancer signaling. 
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2.5 Notes 
This work has been, in part, published in ACS Medicinal Chemistry Letters. 
Xiaokai Li performed chemical synthesis of all compounds, in addition to screening of 
compounds in MDA-MB-231 cells, and in vitro binding studies by ELISA. Sharan R. 
Srinivasan performed screening of compounds in MCF-7 and MDA-MB-231 cells and 
docking studies along with Bryan Dunyak. Jamie Connarn helped with pharmacokinetic 
studies. Atta Ahmad performed NMR titration experiments. Zapporah T. Young and 
Adam M. Kabza also performed experiments. Genomic shRNA screens were completed 
by Martin Kampmann and Luke Gilbert in collaboration with the Weissman Lab at 
UCSF. Xiaokai Li, Sharan R. Srinivasan, and Jason E. Gestwicki helped in the 
preparation of the manuscript. 
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2.6 Experimental Procedures 
 
2.6.1 Chemistry 
 Details of all chemical procedures, including synthesis and characterization of all 
compounds have been described in full in Li et al (2013) (47). 
 
2.6.2 NMR Titration 
 DnaK’s nucleotide-binding domain (DnaKNBD; residues 1-388) was expressed in 
BL21 cells using M9 media enriched with 15N. The cells were induced at an OD600 = 0.5 
and grown overnight at 26 °C. Cells were harvested at 12,227 x g, lysed with sonication 
(Fischer scientific model 500) and the lysate centrifuged at 27,216 x g. The supernatant 
was loaded on a pre-equilibrated FFQ (DEAE type anion exchanger) column. Fractions 
of eluent were identified for protein by OD280 and SDS-PAGE. Fraction containing 
DnaKNBD were pooled, dialyzed and loaded on a pre-equilibrated ATP-agarose column. 
The column was washed with buffer (25 mM TrisHCl, 10 mM KCl, pH 7.0) and eluted 
with 5 mM ADP in buffer. The concentration of the pooled protein fractions was 
determined by the BCA assay. 
NMR samples of 160 µM 15N labeled DnaKNBD (1-388) in 25 mM TrisHCl, 10 mM 
KCl, 8 mM MgCl2, 10 mM PO42-, 0.015% NaN3, 5% D2O and pH 7.0 was divided into 
two 300 µL samples. TROSY-HSQC spectra were then recorded for 3 hrs on a 800 
MHz NMR magnet. The samples were treated with 6 µL of either DMSO alone or JG-98 
(200 µM). TROSY-HSQC data was processed in NMR PIPES and converted to 
SPARKY format. Spectra were manually analyzed in SPARKY. Residues that shift in 
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the JG-98-treated sample, but not the DMSO-treated sample were mapped on the 
crystal structure of DnaKNBD (PDB ID: 2KHO) in PyMOL. 
 
2.6.3 Cell Culture 
MCF-7 cells were cultured in DMEM with 10% fetal bovine serum (Invitrogen) 
and 1% penicillin-streptomycin (Invitrogen). MDA-MB-231 cells were cultured in DMEM 
with 10% FBS, 1% pen-strep, and 1% non-essential amino acids. All cells were 
maintained at 37 oC with 5% CO2 in a humidified atmosphere. 
 
2.6.4 Cell Survival Assay 
Cell viability was determined using a methyl thiazoyl tetrazolium (MTT) 
colorimetric assay (ATCC, catalog number 30-1010K) with the following modifications. 
Briefly, cells (5 x 103) were plated into 96-well assay plates in 0.1 ml media and allowed 
to attach overnight. Cells were then treated with compound at various concentrations in 
0.2 mL media. After the 72-hour incubation period, cells were washed in PBS (3 x 200 
µL), and 10 µL MTT reagent was added with 100 µL fresh media. Cells were then 
incubated for 4 hr in a humidified chamber at 37 ºC with 5% CO2. Insoluble formazan 
crystals were solubilized by addition of 0.1 mL detergent solution (4 hr at room temp., 
dark). Resulting colored solutions were then quantified at an absorbance of 570 nm. 
 
2.6.5 Microsomal Stability Assay 
 LC-MS/MS parameters were optimized for each compound (see below). The 
enzyme β-NADPH (16.6 mg/mL) and master mix; 0.1 M phosphate buffer with 3.3 mM 
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MgCl2, mice liver microsomes (final concentration 500 µg/mL), and compound of 
interest (final concentration 1 µM) were incubated for 3 minutes at 37 ºC. To begin the 
metabolic reaction, 20 µL of β-NADPH was added to the master mix. The reaction was 
incubated at 37 ºC for the duration of the experiment. An aliquot of 40 µL was taken 
from the reaction and added to 120 µL of internal standard (100 nM) in acetonitrile at 
time points 0, 5, 10, 15, 30, and 60 minutes. Samples were centrifuged at 14,000 rpm 
for 15 minutes to extract compound. After samples were analyzed by LC-MS/MS, peak 
areas for the compound and internal standard were plotted again the time to determine 
the half-life. Verapamil was used as a positive control. 
The separation of compounds and internal standard was performed using an 
Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA) and Zobax SB-C18 
column (2.1 × 50 mm, 3.5 µm) (Agilent Technologies). The compounds were eluted with 
a gradient as followed; 0-0.5 min solvent A 90% and solvent B 10%, .51-6 min solvent A 
10% and solvent B 90%, and 6.1- 10min solvent A 90% and solvent B 10%. Solvent A 
contained 0.1% (v/v) FA in water and solvent B contained 0.1% (v/v) FA in acetonitrile. 
Injections of 5 µL of samples were used in the HPLC, the elution ran for 10 minutes at a 
flow of 200 µL/min. The MS detection used a QTRAP 3200 (Applied Biosystems/MDS 
Sciex, Foster City, CA) in the MRM mode. The temperature settings were 500 ºC and 
the curtain gas, gas 1, and gas 2 were 30, 40, and 50 PSIG respectively. The ions 
produced were detected as following; JG-98 channel m/z 498 -> m/z 407. The internal 
standard channel was m/z 400 -> m/z 161. 
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2.6.6 ELISA 
A sample of Hsc70 (50 µL; 0.06 mg/mL) was immobilized in 96-well plates in 
MES buffer (50 mM 2-(N-morpholino)ethanesulfonic acid, pH 5.2) at 37 °C overnight. 
Wells were washed three times with 150 µL TBS-T buffer (25 mM Tris, 140 mM NaCl, 
2.7 mM KCl, 0.01% Tween-20, pH 7.4), then biotin labeled compound (final 
concentration 1 µM; 25 µL) was added and the mixture was incubated at room 
temperature for 3 hrs. The wells were washed again with 150 µL TBS-T three times 
prior to blocking with 100 µL 3% bovine serum albumin (BSA) in TBS-T for 5 min at 
room temperature. After the removal of the blocking solution, 50 µL of HRP-streptavidin 
(Pierce Biotechnology, 1:50000 TBS-T dilution) solution was added and the plates were 
incubated at room temperature for 1 hr. The HRP-streptavidin solution was removed 
and wells were washed three times with TBS-T. TMS substrate (Cell Signaling 
Technology 100 µL) was added and incubated at room temperature until a visible blue 
color was observed (~20 min). 1 M HCl stop solution was then added and the 
absorbance at 450 nm was recorded on a SpectraMax M5 multimode plate reader 
(Molecular Devices). 
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2.7 Appendices 
 
2.7.1 Biotinylated MKT-077 Analogs Bind Hsc70 
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2.7.2 MKT-077 Derivatives Exhibit Preferential Dependence on mtHsp70 
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